ALNYLAM PHARMACEUTICALS, INC. Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ALNYLAM PHARMACEUTICALS, INC. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2026-06-30 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2026-03-31 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2025-09-30 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. shares issued, value, share-based payment arrangement, before forfeiture for fiscal 2025 was $20.50M, a 17.57% increase from fiscal 2024.
- ALNYLAM PHARMACEUTICALS, INC. shares issued, value, share-based payment arrangement, before forfeiture for fiscal 2024 was $17.43M, a 6.12% increase from fiscal 2023.
- ALNYLAM PHARMACEUTICALS, INC. shares issued, value, share-based payment arrangement, before forfeiture for fiscal 2023 was $16.43M, a 19.69% increase from fiscal 2022.
- ALNYLAM PHARMACEUTICALS, INC. shares issued, value, share-based payment arrangement, before forfeiture for fiscal 2022 was $13.72M, a 0.69% increase from fiscal 2021.
| Period end | Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture 3 month | Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture 12 month |
|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $0.00 10-Q · filed 2026-07-30 | |
| 2025-12-31 | $20.50M 10-K · filed 2026-02-12 | |
| 2025-09-30 | $0.00 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $0.00 10-Q · filed 2026-07-30 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-07-30 | |
| 2024-12-31 | $17.43M 10-K · filed 2026-02-12 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-10-30 | |
| 2024-06-30 | $10.36M 10-Q · filed 2025-10-30 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-10-30 | |
| 2023-12-31 | $16.43M 10-K · filed 2026-02-12 | |
| 2023-09-30 | $0.00 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $9.98M 10-Q · filed 2024-10-31 | |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $13.72M 10-K · filed 2025-02-13 | |
| 2022-09-30 | $3.00K 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $8.09M 10-Q · filed 2023-11-02 | |
| 2022-03-31 | $0.00 10-Q · filed 2022-10-27 | |
| 2021-12-31 | $13.63M 10-K · filed 2024-02-15 | |
| 2021-09-30 | $0.00 10-Q · filed 2022-10-27 | |
| 2021-06-30 | $7.72M 10-Q · filed 2022-10-27 | |
| 2021-03-31 | $0.00 10-Q · filed 2022-10-27 | |
| 2020-12-31 | $11.08M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $129.00K 10-Q · filed 2021-10-28 | |
| 2020-06-30 | $5.30M 10-Q · filed 2021-10-28 | |
| 2020-03-31 | $0.00 10-Q · filed 2021-10-28 | |
| 2019-12-31 | $7.91M 10-K · filed 2022-02-10 | |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $4.02M 10-Q · filed 2020-11-05 | |
| 2019-03-31 | -$58.00K 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $5.05M 10-K · filed 2021-02-11 | |
| 2018-09-30 | -$545.00K 10-Q · filed 2019-10-31 | |
| 2018-06-30 | $3.12M 10-Q · filed 2019-10-31 | |
| 2018-03-31 | -$123.00K 10-Q · filed 2019-10-31 | |
| 2017-12-31 | $3.16M 10-K · filed 2020-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |